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Paul Emery1,2Abstract
This short article hypothesizes that the major reason
for persistent disease despite biologic therapy is the
inappropriately late timing of therapy with biologic
agents. There is clear evidence to support this
hypothesis. This short review will indicate that patients
treated at an earlier phase of disease can achieve a
clinical remission rate of 70% and a response rate of
above 95%.For patients with RA, biologic treatment is introduced atThe majority of studies of rheumatoid arthritis (RA)
have shown that when patients with RA are treated with
biologics, they achieve a remission rate of only 30% or
less. There are many potential reasons why disease activ-
ity is incompletely suppressed by biologics. The most
commonly used biologics are anti-cytokines, in particu-
lar those that block TNF alpha. Therefore, a logical
reason for persistent disease activity is either incomplete
blockade of the individual cytokine or the fact that mul-
tiple cytokines/alternative mechanisms are implicated in
the pathogenesis. A pragmatic second reason is that the
outcome measures used to measure response include
elements other than disease activity/inflammation. Even
when inflammation is completely switched off, these
outcome measures may not normalize. An example of
this is the reduced impact of inflammation-suppressive
therapy on outcome measures in later disease, at a time
when there is already extensive damage.
This short article, representing a personal view, will
examine the hypothesis that a major reason there is per-
sistent disease activity is that anti-cytokine biologics are
used inappropriately late in the disease. In patients with
late disease, the disease activity score (DAS) reflectsCorrespondence: p.emery@leeds.ac.uk
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2014damage as well as inflammation and therapy has a large
irreversible component. More controversially, the patho-
genesis of the disease by this time may have evolved, so
that the disease process is less reversible with the blockade
of a single cytokine. For both of these reasons, TNF block-
ade will produce full benefits only when given early in the
course of disease.The move from inflammation to damage
different stages of disease. These stages can be described
in terms of the therapy previously received by the pa-
tient. The first stage is the methotrexate (MTX)-naïve
patient, the next is the MTX incomplete responder (IR),
and the last is TNF inhibitor IR. With movement across
the sequence of stages, increasing duration of disease is
observed as well as increased complexity of pathogen-
esis. This latter fact is linked to the partial resistance of
the disease to conventional therapy later in the disease
course.
The most commonly studied population treated with
biologics consists of MTX IR patients with continued
disease activity. Such patients fulfill National Institute for
Health and Care Excellence guidelines for reimbursement
of therapy and worldwide represent the majority of the
population treated with biologics. In these patients, the
American College of Rheumatology 20% improvement
criteria (ACR20), ACR50, and ACR70 responses observed
are approximately 60%, 40%, and 20%, respectively [1].
The conventional interpretation of these results is that
blockade of TNF produces major suppression of disease
in only a minority of patients. The corollary of this is that
a very significant part of the disease activity (inflamma-
tion) is TNF-independent. Thus, the conventional answer
to the question ‘Why is there persistent disease despite
biologic therapy?’ is that the disease processes are not
completely blocked by inhibition of the cytokine. This
short report will focus on some flaws in this analysis by
examining responses in very early patients treated fromhe licensee has exclusive rights to distribute this article, in any medium, for 6
e, the article is available under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly cited.
Emery Arthritis Research & Therapy Page 2 of 42014, 16:115
http://arthritis-research.com/content/16/3/115onset with combination MTX and a biologic which
inhibits TNF.
The phenotype of methotrexate incomplete
responder patients
It is possible to determine relatively quickly whether a
patient is failing MTX. However, the majority of patients
classified as MTX IR patients not only will have been
taking MTX for a considerable time but also will have
substantial disease duration. Patients often have had a
diagnosis made several years earlier and therefore will
fall into the category of late-disease treatment (reviewed
by Aaltonen and colleagues [1]). In addition (as men-
tioned above), they may well have more complex disease
which is less responsive to TNF blockade alone than in
MTX-naïve patients.
Methotrexate-naïve patients
In Figure 1, it is clear that MTX-naïve patients achieve
better clinical responses to biologics than those reported
for either MTX IR or TNF IR. However, even within this
population of essentially disease-modifying anti-rheumatic
drug-naïve patients, differences in response are seen
according to disease/symptom duration. Perhaps the best
example of this is the COMET (Combination of Metho-
trexate and Etanercept in Active Early Rheumatoid
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Figure 1 Remission rates across rheumatoid arthritis studies accordin
study to Gauge Remission and joint damage progression in methotrexate-n
Controlled Study of Patients Receiving Infliximab for the Treatment of Early
and Etanercept in Active Early Rheumatoid Arthritis; DAS, disease activity sc
Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arth
(MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthriti
of Etanercept versus Standard of Care in Early Rheumatoid Arthritis.with MTX and etanercept. The patients were all MTX-naïve
and had relatively short disease duration (maximum of
2 years) [2]. The remission rate for the combination was
50%. However, on the basis of the arguments developed in
this article, it was decided to re-examine the data accord-
ing to whether the patients were treated within the first
4 months of their disease. In these patients, remission
rates for the combination therapy rose to 70%, whereas
those for MTX remained roughly the same at 30% [3].
Furthermore, when patients who had toxicity are
excluded, virtually everybody responded.
Although this could be seen as a ‘one off ’, it has re-
cently been reproduced by other studies: the first is a
double-blind randomized controlled study [9] which
produced remission rates in the combination MTX and
etanercept arm of 68% in patients with very early RA in-
flammatory arthritis; in the second study, PRIZE (Prod-
uctivity and Remission in a Randomized Controlled
Trial of Etanercept versus Standard of Care in Early
Rheumatoid Arthritis), patients in early disease were
treated in an open fashion with an intention-to-treat
remission rate of 70.5% [10] (Figure 2). The reversibility
of inflammation and response to TNF blockade of early
disease are clearly seen in the EMPIRE (Etanercept and
Methotrexate to Induce Remission in Patients With
Newly Diagnosed Inflammatory Arthritis) study, in
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Figure 2 Remission rates in early rheumatoid arthritis with etanercept/methotrexate. a[9]; b[3]; c[10]. COMET, Combination of Methotrexate
and Etanercept in Active Early Rheumatoid Arthritis; DAS, disease activity score; EMPIRE, Etanercept and Methotrexate to Induce Remission in
Patients With Newly Diagnosed Inflammatory Arthritis; MTX, methotrexate; PRIZE, Productivity and Remission in a Randomized Controlled Trial of
Etanercept versus Standard of Care in Early Rheumatoid Arthritis.
Note
This article is part of the collection ‘Why is there persistent disease
despite aggressive therapy of rheumatoid arthritis?’, edited by Pierre
Miossec. Other articles in this series can be found at http://arthritis-
research.com/series/residual.
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ported by previous studies: a randomized controlled
study [11] and an open study of infliximab in very early
disease treated at presentation had shown over 90% re-
mission rates at week 14 in patients [12]. The former
study also demonstrated maintenance of remission at
2 years, 1 year after stopping biologics. Thus, treating
produces a magnitude of response not seen or achiev-
able later and in that sense could be viewed as a window
of opportunity.
Summary
When patients are treated at the start of disease with a
blockade of TNF and MTX, the following occur:
1. There is an extremely rapid response (38% at
2 weeks) [9].
2. The majority of patients achieve remission, and few
have persistent inflammation [3].
3. It does appear that long-term benefit can ensue
(with DAS benefits sustained at 8 years) [13].
4. Therefore, the logical time to use anti-cytokine
agents to induce remission is at presentation.
Is there an explanation for this? Biomarkers do seem
to indicate a change in T-cell phenotype over time (loss
of memory T cells), which does correlate with respon-
siveness to MTX [14]. Furthermore, there do appear tobe two types of signaling: one cytokine-dependent, the
other largely cytokine-dependent [15]. It is conceivable
that the relative importance of these two signaling
pathways changes over time.Abbreviations
ACR20: American College of Rheumatology 20% improvement criteria;
DAS: Disease activity score; IR: Incomplete responder; MTX: Methotrexate;
RA: Rheumatoid arthritis; TNF: Tumor necrosis factor.
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